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predictive of AF development (Table).
Conclusions:
BMI was an independent predictor of first AF in this study of older adults. The potential
contribution of obesity to AF development warrants special attention, given the alarming
prevalence of both these public health problems.
11:45 a.m.
885-6 Prognostic Implications of Admission Hyperglycemia in 
Elderly Patients With Acute Myocardial Infarction
Mikhail Kosiborod, Saif S. Rathore, Yongfei Wang, Silvio E. Inzucchi, Frederick A. 
Masoudi, Edward P. Havranek, JoAnne M. Foody, Harlan M. Krumholz, Yale University 
School of Medicine, New Haven, CT, Denver Health Medical Center, Denver, CO
Background: Prior reports suggested that hyperglycemia is associated with poor out-
comes in patients (pts) with acute myocardial infarction (AMI), but were limited by size
and geographic constraints. We sought to examine the prognostic implications of hyperg-
lycemia in a large representative sample of elderly pts with AMI.
Methods: We evaluated a national sample of Medicare pts directly admitted for con-
firmed AMI between 1994-96, restricting analysis to pts >65 years with admission plasma
glucose of 50-600 mg/dL, known survival status and no terminal illness (n=142,060). Pts
were divided into quartiles (Q) based on admission glucose (Q1 50 - 119, Q2 120 - 149,
Q3 150 - 209, Q4 210-600 mg/dL). Multivariable logistic regression was used to test the
association between glucose and mortality at 30 days and 1 year.
Results: Higher glucose was associated with increased mortality at 30 days (Q1 11.4%,
Q2 14.8%, Q3 20.4%, Q4 27.1%, P<0.001) and 1 year (Q1 23.4%, Q2 27%, Q3 34.4%,
Q4 43.8%, P<0.001). This trend persisted in pts without known history of diabetes (DM)
for 30 day (Q1 11%, Q2 14.8%, Q3 22.1%, Q4 36.8%, P<0.001) and 1 year mortality (Q1
22.3%, Q2 26.4%, Q3 35.1%, Q4 52.4%, P<0.001). Adjusted mortality remained higher
in all pts with hyperglycemia, including those without prior history of DM (Table).
Conclusion: Admission hyperglycemia is associated with higher mortality in elderly pts
with AMI, including those without antecedent diagnosis of DM. Whether hyperglycemia is
a marker or mediator of higher risk is unknown.
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887-1 Combined Effects of Diastolic Dysfunction and Left 
Ventricular (LV) Remodeling on Mortality in 7,267 
Patients With Preserved LV Systolic Function
Richard V. Milani, Mandeep R. Mehra, Carl J. Lavie, Hector O. Ventura, Ochsner Clinic 
Foundation, New Orleans, LA
Background: We and others have published the adverse effects of diastolic dysfunction
(DD) and LV geometric patterns on mortality. To our knowledge the combined effects of
DD and LV remodeling has not been examined.
Methods: We assessed the impact of DD on mortality in patients with various LV struc-
tural profiles from a large echocardiographic database (n=7,267) and with normal systolic
function (EF >= 50%) (mean follow-up 3.1 years). Based on previously published criteria
utilizing relative wall thickness (RWT) (2 x posterior wall thickness / LV end diastolic
diameter; increased > 0.43), and LV mass index (LVMI) (increased > 104 g/m2 in women
and > 116 g/m2 in men), we classified patients as normal (normal RWT and LVMI), CR
(increased RWT, normal LVMI), CH (increased RWT and increased LVMI) and EH (nor-
mal RWT, increased LVMI). DD was identified based on established Doppler derived
mitral inflow patterns.
Results: The prevalence of normal cardiac structure was 54% (n=3,924), CR 35%
(n=2,543), EH 5% (n=363) and CH 6% (n=436). See figure for mortality results.
Conclusions: Cardiac remodeling in patients with preserved LV systolic function is asso-
ciated with an increase in mortality. DD nearly doubles mortality in all LV structural pro-
files and is particularly pathogenic when identified with adverse remodeling.
10:45 a.m.
887-2 Cardiogenic Shock in Patients With Preserved Left 
Ventricular Systolic Function: Characteristics and 
Insight Into Mechanisms
Krishnan Ramanathan, Shannon M. Harkness, Ambika C. Nayar, John E. Cosmi, Lynn S. 
Sleeper, Harvey D. White, Ravin Davidoff, Judith S. Hochman, New York University 
School of Medicine, New York, NY
Background: Traditionally, very poor left ventricular (LV) function with low ejection frac-
tion (EF) is considered the hallmark necessary for developing cardiogenic shock (CS)
due to predominant LV failure in acute myocardial infarction (MI). In the SHOCK trial,
patients with preserved (LVEF) developed CS, challenging this paradigm. We report the
clinical and 2-D echocardiographic (Echo) characteristics of patients with preserved
LVEF in the SHOCK trial and suggest a mechanism for CS post-MI.
Methods: We retrospectively studied SHOCK trial (n=97) patients who had core lab
assessment of Echo performed at the time of randomization and before revasculariza-
tion, excluding patients with a mechanical cause of CS. The patients were subdivided
into quartiles (Q1 to 4) based upon initial LVEF for comparison between Q1 (EF >37%;
n=24) and Q2-4 (EF </=37%).
Results: The Q1 group had lower incidence of prior MI or history of hypertension (38
vs.73%), lower mean pulmonary wedge pressure (21 ±8 vs. 24±7mmHg; p<0.05 for both)
and a trend towards lower heart rate (94±25 vs.103±21 per min; p=0.09).
Otherwise the groups had similar baseline characteristics, thrombolytic use, peak CPK,
initial hemodynamics, cardiac index, SVR and time from CS diagnosis to LVEF measure
(median 4.8 vs.7.1h; p=0.78). The groups were similar for right ventricular size and func-
tion, remote zone wall motion score index and mitral or aortic regurgitation. In 35 patients
with measure of transmitral filling patterns, the prevalence of a restrictive filling pattern
defined as E:A ratio>2 or E:A ratio 1-2 with MDT <141msec was similar in both groups
(p=0.06). The Q1 group had significantly lower LV end-diastolic (96± 45 vs. 119± 38 ml)
and end-systolic volume and a higher proportion with normal LV size range (79 vs. 42%)
and EF (47±7 vs. 25±7%) p<0.01 for all. Although stroke volume index (SVI) was higher
in Q1 (34 ± 22 vs 21± 10ml/m2; p<0.01), it was low for all groups.
Conclusions: Patients developing CS with an EF >37% have non-dilated, small sized-
LVs. We propose that acute LV dilation is an adaptive compensation for large MIs to
maintain SV and lack of acute dilation predisposes to CS, perhaps most importantly in
association with abnormal vascular tone.
11:00 a.m.
887-3 What Proportion of Patients With Heart Failure and 
Preserved Left Ventricular Systolic Function Has an 
Elevated Plasma Concentration of B-Type Natriuretic 
Peptide?
Karen J. Hogg, Esther Rooney, Eileen Lundmark, James Christie, Edward Newman, 
David Kay, John J.V McMurray, Glasgow University, Glasgow, United Kingdom
BACKGROUND: Many patients admitted to hospital with a clinical diagnosis of “heart
failure” are found to have preserved left ventricular (LV) systolic function. There remains,
however, a great deal of uncertainty as to whether or not these patients really do have
heart failure. We have determined the proportion of such patients in which there is bio-
chemical evidence of LV compromise i.e. those who have an increased plasma concen-
tration of B type natriuretic peptide (BNP).
METHODS: 2725 near consecutive emergency admissions were screened for clinical
signs of heart failure. 167 fulfilled the criteria and had heart failure according to at least
one of the three standard heart failure classification systems (Boston, NHANES and
Framingham). Their mean age was 75 years and 56% were female. Trans-thoracic
echocardiography (TTE) was performed and plasma BNP concentrations measured. An
Multivariate clinical model for prediction of AF
Variable HR 95%CI P-value
Age, year 1.044 1.025-1.065 <0.0001
Male gender 1.344 1.014-1.781 0.0397
Valvular heart disease 1.750 1.264-2.423 0.0007
History of congestive heart failure 2.778 1.986-3.885 <0.0001
History of myocardial infarction 1.805 1.330-2.452 0.0002
Diabetes mellitus 1.208 0.800-1.822 0.3687
Hypertension 1.418 1.071-1.878 0.0147
BMI, per 10 kg/m2 1.335 1.027-1.736 0.0309
Risk ratios with 95% confidence intervals
Q1 Q2 Q3 Q4
All patients
30-day mortality 1.00-referent 1.21 (1.17, 1.27) 1.51 (1.44, 1.57) 1.93 (1.84, 2.01)
1-year mortality 1.00-referent 1.13 (1.09, 1.16) 1.31 (1.27, 1.35) 1.57 (1.52, 1.62)
Patients without diabetes
30-day mortality 1.00-referent 1.25 (1.20, 1.31) 1.59 (1.52, 1.67) 2.03 (1.92, 2.13)
1-year mortality 1.00-referent 1.15 (1.11, 1.18) 1.36 (1.32, 1.41) 1.66 (1.59, 1.73)
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elevated BNP was defined as a concentration above the upper 95th percentile of a nor-
mal range established from a local healthy population.
RESULTS: Of the 147 patients who had clinical evidence of heart failure and both TTE
and BNP results were available, 62% had preserved LV systolic function. 62% of this
group were female (mean age 75 years). The median (range) BNP in patients with
reduced LV systolic function was 589 pg/ml (12-3117) compared to 190 pg/ml (1-2785) in
patients with preserved LV systolic function (p<0.0001). 71% of patients with preserved
LV systolic function had an elevated plasma BNP concentration. However, 43% of this
group also had valve disease or atrial fibrillation. Overall, 41% of patients with clinical
heart failure and preserved LV systolic function had an elevated plasma BNP concentra-
tion and no valve disease or atrial fibrillation.
CONCLUSION: Of all the patients fulfilling standard diagnostic criteria for heart failure
and who had preserved LV systolic function, 41% had biochemical evidence of LV com-
promise and did not have valve disease or atrial fibrillation.
11:15 a.m.
887-4 Patients With the Metabolic Syndrome Have a High 
Prevalence of Left Ventricular Diastolic Dysfunction
Sheng-Jing Dong, Lisa de las Fuentes, Angela L. Brown, Alan D. Waggoner, Sharon L. 
Heuerman, Robert J. Gropler, Victor G. Davila-Roman, Washington University, St Louis, 
MO
Background: Previous studies have shown the utility of transmitral pulse-wave Doppler-
derived (PWD) indices for the detection of left ventricular diastolic dysfunction. Tissue
Doppler imaging (TDI) is a relatively load-independent method used to assess abnormal
LV relaxation. The prevalence of diastolic dysfunction in the metabolic syndrome has not
been well evaluated.
Methods: 94 subjects were evaluated for variables of metabolic syndrome: 1) waist cir-
cumference > 102 cm in men or > 88 cm in women; 2) triglycerides > 150 mg/dl; 3) HDL
< 40 mg/dl in men or < 50 mg/dl in women; 4) diabetes or fasting blood glucose > 110
mg/dl; 5) history of hypertension or BP > 130/85. 22 subjects (age:43±9, 59% female)
met none (Group 1), 53 (age:48±14, 47% female) met 1-2 (Group 2) and 19 (age:59±8,
51% female) met > 3 criteria of metabolic syndrome (Group 3). Echocardiographic exam-
ination included measurements of ejection fraction (LVEF), LV mass index (LVMI), PWD
transmitral early and late filling velocities (E and A), deceleration time (DT) and TDI-
derived early myocardial velocity at the septal mitral annulus (Em). Based on PWD, nor-
mal diastolic filling (NF) was defined as E/A> 1 and DT = 170-230 ms; impaired relax-
ation (IR) as E/A < 1 and DT > 230 ms; pseudonormalized filling (PN) as E/A > 1 and DT
< 170 ms; and restrictive filling (RF) as E/A > 2 and DT < 170 ms. A TDI-derived Em < 8
cm/s identified abnormal relaxation.
Results: All subjects had normal EF (64 ± 8%). 26 subjects had LVH: 4 (19%) in Group
1, 13 (25%) in Group 2 and 9 (47%) in Group 3. Among subjects unclassifiable by PWD
criteria (n = 21, 22%), TDI allowed reclassification of 16 patients as NF and 5 as IR.
Among those with discordant classification (n = 19, 20%), 3 patients identified as NF by
PWD had IR by TDI, and 16 patients with abnormal diastolic filling [IR (4 patients), PN (7
patients) or RF (5 patients)] by PWD were normal by TDI. Using TDI criteria, the preva-
lence of diastolic dysfunction was 5% in Group 1, 21% in Group 2 and 37% in Group 3.
Conclusions: Patients with metabolic syndrome have a high prevalence of abnormalities
in LV diastolic function. This finding may have important implications in long-term cardio-
vascular morbidity and mortality.
11:30 a.m.
887-5 Diastolic Heart Failure in Patients Hospitalized With 
Symptomatic Cerebral and Peripheral Vascular Disease
Robert V. Kelly, Esq., Walter Tan, E Magnus Ohman, Allan D. Struthers, University of 
North Carolina, Chapel Hill, NC, University of Dundee, Dundee, Scotland, United 
Kingdom
Background: Patients with Stroke, TIA and claudication are at an increased risk for mor-
bidity and mortality from systolic heart failure (CHF) and ischaemic heart disease. We
have previously reported five times more CHF in these patients compared with the gen-
eral population. Heart failure with preserved LV function/ diastolic heart failure (DHF) is
associated with increased morbidity and hospitalizations in the general population at a
rate similar to that seen in CHF. However, the prevalence of diastolic heart failure (DHF)
in patients presenting with acute cerebral and peripheral vascular syndromes is
unknown.
Methods: Two hundred and twenty-one prospective consecutive patients presenting with
their first stroke, TIA or new onset of claudication underwent history, exam, ECG and
echocardiography. Diastolic heart failure (DHF) was defined as EF>45% + Framingham
signs and symptoms of heart failure. Asymptomatic LV systolic dysfunction (aLVSD) was
defined as an EF<45%.
Results: 
Conclusions: Diastolic heart failure is found in 15% of patients who present to hospital 
with acute vascular syndromes. It is equal in prevalence to systolic HF. Therefore, close 
to two-thirds of patients with symptomatic vascular disease have co-morbid heart failure 
Patients with DHF tend to have a higher prevalence of PVD and less symptomatic cere-
brovascular events compared with CHF patients despite being older and with more 
hypertension, diabetes and atrial fibrillation.
11:45 a.m.
887-6 Treatment With Inhibitors of Angiontensin-Converting 
Enzyme Improves the Prognosis of Congestive Heart 
Failure With Preserved Systolic Function
Varela Alfonso, Gonzalez-Juanatey Jose Ramón, Grigorian Lilian, Bassante Patricia, 
Barge Eduardo, Pedreira Milagros, Martinez-Sande Luis, Bandín Manuel Angel, García-
Seara Javier, Mazón Pilar, Gil de la Peña Miguel, Hospital Clinico Universitario, Santiago 
de Compostela, Spain
Inhibitors of angiotensin-converting enzyme (ACE) improve the prognosis of congestive
heart failure (CHF) involving systolic dysfunction (SD), but hitherto it has not been known
whether the same is true for CHF without SD. This study compared the effects of ACE
inhibitors on the survival of hospitalized CHF patients with and without SD. Among the
patients hospitalized for CHF in the Cardiology Service of a tertiary hospital between
1991 and 2002, we studied the 958 (aged 69.7
 
±
 
11.7 years) whose left ventricular sys-
tolic function had been evaluated echocardiographically during admission. Of these, 581
(60,6%) were men, 541 (56.5%) had arterial hypertension, 263 (27.5%) were diabetics,
398 (41.5%) were in NYHA class IV, 462(48.2%) had ischaemic cardiopathy (the most
common aetiology), and 610 (63.7%) took ACE inhibitors following admission for CHF.
Ejection fraction was <
 
50% in 572 (59.7%) and >
 
50% in 386 (40.3%). Survival curves
show treatment with ACE inhibitors to have benefited both these groups to a statistically
significant degree.
Conclusion: ACE inhibitors lengthen the lives of CHF patients whether or not they have
systolic dysfunction. 
Clinical variables Normal LV
(n=83)
Diastolic HF
(n=32)
Systolic HF
(n= 34)
aLVSD
(n=72)
Mean age (years)
Female gender (%)
68
52 (63)
71
16 (50)
69
13 (38)
65
24 (33)
Stroke (%)
TIA
PVD
29 (35)
24 (30)
29 (35)
10 (31)
10 (31)
12 (38)
12 (35)
14 (41)
8 (24)
23 (31)
26 (38)
23 (31)
IHD/ MI (%)
Hypertension
Diabetes
Prior CABG
Smokers
Hypercholestrol
6 (7)
46 (55)
8 (10)
0 (0)
68 (82)
10 (31)
15 (47)
20 (63)
5 (16)
5 (16)
27 (84)
10 (31)
18 (53)
16 (47)
4 (12)
7 (21)
29 (86)
17 (50)
20 (28)
27 (38)
9 (13)
8 (11)
50(69)
33 (46)
Atrial fibrillation (%) 6 (7) 4 (13) 3 (8) 10 (14)
